The American Journal on Addictions
January 28, 2026
Mariana C De Oliveira, Cláudia C De Araujo Palmeira, André B Negrão et al.
1 citation
Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25-year-old woman with OUD, chronic pain, and major depressive disorder underwent an 8-week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Methadone dosage was reduced by 50%, with improved pain and craving control,...
The American Journal on Addictions
September 1, 2025
Valerio Ricci, Domenico de Berardis, Giovanni Martinotti et al.
AbstractBackground and ObjectivesCannabis use is associated with psychotic disorder onset and exacerbation. This study examines how continued cannabis use affects depressive symptoms, psychotic symptoms, and suicidal behaviors following cannabis‐induced first‐episode psychosis (FEP).MethodsSixty‐five participants (aged 16–50 years) with FEP were recruited from psychiatric inpatient facilities...
The American Journal on Addictions
May 10, 2025
Jessica Van Denend, Jeremy Weleff, Kelly Park et al.
Within substance use research, religion and spirituality (r/s) have been understudied in relation to harm reduction approaches. We perform a literature review to characterize various intersections between r/s and harm reduction. We searched major databases, Google Scholar, and other sources for academic articles and gray literature on the intersection between r/s and harm reduction. We describe...
The American Journal on Addictions
May 1, 2024
Michael Rogan, Julio C Nunes, Catherine Z Xie et al.
2 citations
Childhood trauma (CT) increases addiction vulnerability. We examined CT's impact on delta-9-tetrahydrocannabinol (THC) effects. This is a post-hoc analysis of a randomized, placebo-controlled, crossover trial investigating the effects of oral THC (10, 20 mg) among 25 persons receiving methadone for opioid use disorder (OUD). Greater CT was associated with lower aversive effects from higher THC...
The American Journal on Addictions
November 1, 2023
Amanda Kim, Joji Suzuki
15 citations
In recent years, there has been accelerating scientific and public interest in the use of psychedelics to treat mental health disorders. Our study's objective was to assess the attitudes of addiction specialists regarding therapeutic psychedelics. Our study utilized an anonymous online survey to assess the opinions of 145 addiction specialists regarding the therapeutic promise, potential risks,...
The American Journal on Addictions
November 1, 2022
Mariam Kyarunts, Meghna P. Mansukhani, Larissa L. Loukianova et al.
26 citations
AbstractBackground and ObjectivesPatients increasingly rely on the Internet for healthcare information. This study aimed to evaluate the quality of videos on 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy for posttraumatic stress disorder (PTSD) on YouTube™.MethodsYouTube™ was searched for the terms “MDMA” and “PTSD.” The 100 most viewed videos were analyzed using three...
The American Journal on Addictions
April 1, 2018
Joseph El-Khoury, Evelyne Baroud
3 citations
Recreational use of salvia divinorum (salvia), a potent, naturally occurring hallucinogen, is on the rise internationally. Despite the paucity of information about its long-term health effects, salvia is readily available and generally portrayed as a safe non-addictive substance. We report on two patients who presented with an enduring and pervasive pattern of salvia use. Evaluating patients...
The American Journal on Addictions
August 1, 2016
Joseph J Palamar, Monica J Barratt, Jason Ferris et al.
49 citations
Although new psychoactive substances (NPS) continue to emerge at a rapid rate, US national surveys only measure the use of non-specific categories of NPS and are not designed to access high-risk populations. In this paper we report lifetime use of specific NPS (of 58) and examine correlates of use among a high-risk population: nightlife attendees. The self-selected sample from the Global Drug...
The American Journal on Addictions
April 1, 2015
Cole Marta, Wesley C Ryan, Alex Kopelowicz et al.
17 citations
Ibogaine is a naturally occurring hallucinogen with postulated anti-addictive qualities. While illegal domestically, a growing number of individuals have sought it out for treatment of opiate dependence, primarily in poorly regulated overseas clinics. Existing serious adverse events include cardiac and vestibular toxicity, though ours is the first report of mania stemming from its use. To...
The American Journal on Addictions
2014
Bob Prue
16 citations
Peyote was classified as a hallucinogen in the Drug Abuse Control Act of 1965, leaving American Indian (AI) religious use in legal ambiguity. In 1994, the American Indian Religious Freedom Act was amended to unambiguously protect the right of religious use of peyote for AIs. The purpose of this article is to report the prevalence rates of peyote use by AIs compared to the rest of the US...
The American Journal on Addictions
November 1, 2012
Alexander Baldacchino, Zoe Hughes, Michael Kehoe et al.
The term "cannabis psychosis" has become ubiquitous in the psychiatric literature. Few authors have described the precise psychopathology of this potentially distinct subtype of psychosis. Specifically, little attention has been paid to exploring whether cannabis psychosis is characterized by a psychopathology which is different from that of other types of psychosis. The purpose of this paper...
The American Journal on Addictions
1999
Kenneth Alper, Howard S. Lotsof, Geerte M. N. Frenken et al.
201 citations
Ibogaine is an alkaloid with putative effect in acute opioid withdrawal. Thirty-three cases of treatments for the indication of opioid detoxification performed in non-medical settings under open label conditions are summarized involving an average daily use of heroin of .64 +/- .50 grams, primarily by the intravenous route. Resolution of the signs of opioid withdrawal without further drug...